A decade of impact: Biogen’s Ice Bucket Challenge for ALS

August 22, 2024: In recognition of the 10th anniversary of the ALS Ice Bucket Challenge, Biogen Australia employees braved the cold to have 10 litres of ice and water poured over them as part of a company-wide challenge, uniting employees in a show of support for amyotrophic lateral sclerosis (ALS) research. 

A decade ago, the ALS Ice Bucket Challenge emerged as more than just a social movement—it became a pivotal force in advancing the fight against ALS and Biogen has been at the forefront of this effort, dedicating over fourteen years to advancing the understanding and treatment of this progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. 

David Henderson, Managing Director at Biogen ANZ commented, “Participating in the Ice Bucket Challenge is a meaningful way for us to honour the progress made over the past decade and reaffirm our commitment to the ALS community. 

“We are inspired by the resilience of those living with the condition and proud of Biogen’s dedication, with this event not only celebrating past achievements but also illustrating our ongoing dedication to ALS research and the pursuit of innovative therapies. 

“Despite the significant challenges in this field, Biogen remains steadfast in its mission to keep working in the most difficult of areas and to not give up in those areas most under-served.” 

Biogen Australia employees nominated each other on LinkedIn to participate as part of a global effort that saw teams in other countries and at the company’s International Headquarters in Switzerland involved, including Biogen’s Regional Presidents who embraced the challenge.

“On this 10^th anniversary of the Ice Bucket Challenge, we continue to be inspired by the ALS community, working together to advance treatment and marvelling at their resilience, their courage and their belief,” said Fraser Hall, President, Head of Biogen Intercontinental Region. Fraser then went on to take the Ice Bucket Challenge as a small token of his appreciation for this community. 

Amyotrophic lateral sclerosis (ALS) is a rare, progressive, and fatal neurodegenerative disease that leads to the loss of motor neurons responsible for voluntary muscle movement. 

Those living with ALS face severe muscle weakness and atrophy, progressively losing the ability to move, speak, eat, and eventually breathe, with an average life expectancy of three to five years from symptom onset.¹

ENDS

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of amyotrophic lateral sclerosis, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialised immunology, and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable, and equitable world. Follow us at www.biogen.com.au.